Dosing Begins in Extension Study of Yeast-derived Treatment for EPI

Dosing Begins in Extension Study of Yeast-derived Treatment for EPI

283723

Dosing Begins in Extension Study of Yeast-derived Treatment for EPI

The first two patients have been dosed in the Phase 2b OPTION 2 extension study evaluating MS1819 in treating exocrine pancreatic insufficiency (EPI) in people with cystic fibrosis (CF), its developer, AzurRx BioPharma, announced in a press release. The thick mucus that accumulates in the organs of people with CF, including the pancreas, can prevent the pancreas from releasing enzymes that are necessary for proper food digestion, resulting in EPI. EPI is generally treated with pancreatic enzyme replacement…

You must be logged in to read/download the full post.